Showing 1,321 - 1,340 results of 18,521 for search '(( a ((linear decrease) OR (larger decrease)) ) OR ( a ((latent decrease) OR (largest decrease)) ))', query time: 0.65s Refine Results
  1. 1321
  2. 1322

    Mechanism of Peroxynitrite Interaction with Ferric <i>M. tuberculosis</i> Nitrobindin: A Computational Study by Andresa Messias (14384003)

    Published 2024
    “…These results indicate that ONOO<sup>–</sup> exhibits a much larger barrier for ligand displacement than ONOOH, suggesting that water displacement is assisted by protonation of the leaving group by the incoming ONOOH.…”
  3. 1323

    Mechanism of Peroxynitrite Interaction with Ferric <i>M. tuberculosis</i> Nitrobindin: A Computational Study by Andresa Messias (14384003)

    Published 2024
    “…These results indicate that ONOO<sup>–</sup> exhibits a much larger barrier for ligand displacement than ONOOH, suggesting that water displacement is assisted by protonation of the leaving group by the incoming ONOOH.…”
  4. 1324
  5. 1325
  6. 1326
  7. 1327
  8. 1328
  9. 1329
  10. 1330
  11. 1331

    Raw data of the charts in Fig 5. by Kam Pui Tam (19746865)

    Published 2024
    “…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”
  12. 1332

    Antibodies used in western blot analysis. by Kam Pui Tam (19746865)

    Published 2024
    “…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”
  13. 1333

    Raw data of the charts in Fig 3. by Kam Pui Tam (19746865)

    Published 2024
    “…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”
  14. 1334

    Raw data of the charts in Fig 1. by Kam Pui Tam (19746865)

    Published 2024
    “…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”
  15. 1335

    Raw data of the charts in Fig 6. by Kam Pui Tam (19746865)

    Published 2024
    “…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”
  16. 1336

    Raw data of the charts in Fig 2. by Kam Pui Tam (19746865)

    Published 2024
    “…We postulate that the combination of bortezomib (proteasome inhibitor) and venetoclax (Bcl-2 inhibitor) [bort/venetoclax] will cause synergistic killing of post-transplant lymphoproliferative disorder (PTLD) through targeting the pro-survival function of latent viral proteins such as latent membrane protein-1 (LMP-1) and EBV nuclear antigen-3C (EBNA-3C). …”
  17. 1337
  18. 1338
  19. 1339
  20. 1340